z-logo
Premium
Effective therapy of human immunodeficiency virus‐associated anemia with recombinant human erythropoietin despite high endogenous erythropoietin
Author(s) -
Dacosta Noshir A.,
Hultin Mae B.
Publication year - 1991
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830360118
Subject(s) - erythropoietin , anemia , medicine , hemoglobin , recombinant dna , human immunodeficiency virus (hiv) , immunology , virology , biology , biochemistry , gene
A 32‐year‐old woman with human immunodeficiency virus (HIV) infection and progressive anemia presented to University Hospital with a hemoglobin of 3.4 g/dl. Because of her religious beliefs, she refused transfusion, and no iron or vitamin deficiency was found. She responded to recombinant human erythropoietin 150 U/kg intramuscularly thrice weekly with a rise in hemoglobin to 9.3 g/dl by 3 months of treatment. The serum erythropoietin level before treatment was markedly elevated at 1,340 mU/ml.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom